Sax Wealth Advisors LLC Acquires 1,532 Shares of Insulet Co. (NASDAQ:PODD)

Sax Wealth Advisors LLC raised its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 101.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,044 shares of the medical instruments supplier's stock after buying an additional 1,532 shares during the period. Sax Wealth Advisors LLC's holdings in Insulet were worth $795,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Blue Trust Inc. grew its position in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after acquiring an additional 58 shares in the last quarter. Venturi Wealth Management LLC lifted its stake in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after purchasing an additional 133 shares during the last quarter. TD Private Client Wealth LLC boosted its holdings in Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after purchasing an additional 56 shares in the last quarter. Friedenthal Financial acquired a new position in Insulet during the fourth quarter worth $57,000. Finally, Versant Capital Management Inc raised its holdings in Insulet by 106.1% during the fourth quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock valued at $80,000 after buying an additional 157 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. JPMorgan Chase & Co. upped their price target on Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research note on Thursday, December 12th. Morgan Stanley upped their price objective on shares of Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a report on Monday, November 11th. Barclays boosted their target price on shares of Insulet from $220.00 to $234.00 and gave the stock an "equal weight" rating in a research report on Monday, November 11th. BTIG Research lifted their price objective on Insulet from $260.00 to $270.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Finally, Citigroup increased their target price on Insulet from $283.00 to $310.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, Insulet presently has an average rating of "Moderate Buy" and an average target price of $272.81.

Insulet Price Performance

PODD traded up $2.95 during midday trading on Friday, reaching $275.81. 554,098 shares of the company's stock were exchanged, compared to its average volume of 448,891. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The business has a 50-day simple moving average of $266.30 and a two-hundred day simple moving average of $232.70. The firm has a market capitalization of $19.35 billion, a price-to-earnings ratio of 47.23, a price-to-earnings-growth ratio of 3.41 and a beta of 1.22. Insulet Co. has a one year low of $160.19 and a one year high of $279.77.

Insider Buying and Selling

In other Insulet news, CAO Lauren Budden sold 915 shares of the company's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares of the company's stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.47% of the stock is owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.